First-in-human study (FIH) of FS222, a next-generation tetravalent PD-L1/CD137 bispecific antibody: Safety, pharmacodynamics (PD), and antitumor activity in patients (pts) with advanced solid tumors including PD-1 refractory melanoma

被引：0
|
作者：
Garralda, Elena
Oberoi, Arjun
de Velasco, Guillermo
Victoria, Ivan
Pesantez, David
Eguren Santamaria, Inaki
Moreno, Victor
Boni, Valentina
Cervantes, Andres
Gambardella, Valentina
Ciuleanu, Tudor-Eliade
Bergamino Sirven, Milana
Rodriguez-Abreu, Delvys
Alonso, Guzman
Minea Gales, Laurentia
Jones, Daniel
Patki, Abhay
Ataman, Ozlem
Melero Bermejo, Ignacio
机构：
[1] Vall dHebron Univ Hosp HUVH, Barcelona, Spain
[2] Vall Hebron Inst Oncol VHIO, Barcelona, Spain
[3] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain
[4] Hosp Clin Barcelona, Barcelona, Spain
[5] Hosp Clin Barcelona, Barcelona, Spain
[6] Clin Univ Navarra, Pamplona, Spain
[7] Hosp Univ Fdn Jimenez Diaz, START Madrid FJD, Madrid, Spain
[8] Univ Hosp Quiron Salud, NEXT Oncol, Madrid, Spain
[9] Hosp Clin Univ Valencia, Valencia, Spain
[10] Inst Oncol Prof Dr Ion Chiricuta, Cluj Napoca, Romania
[11] Univ Med & Pharm Iuliu Hatieganu, Cluj Napoca, Romania
[12] H U Germans Trias & Pujol, ICO Badalona, Barcelona, Spain
[13] Complejo Hosp Univ Insular Materno Infant, Las Palmas Gran Canaria, Spain
[14] Hosp Quironsalud, NEXT Oncol, Barcelona, Spain
[15] Carol Davila Univ Med & Pharm, Bucharest, Romania
[16] InvoX Pharma Ltd, London, England
[17] Clin Univ Navarra, Pamplona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2505
引用
收藏
页数：1
相关论文
共 50 条
  • [21] First-in-human study of ZG005, a dual specific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors
    Qin, Shukui
    Cheng, Ying
    Wu, Lihua
    Chai, Xiaoli
    Wang, Qiming
    Liu, Qinghua
    Fan, Lianlian
    Shi, Jianhua
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Preliminary phase I results from a first-in-human study of EMB-02, a PD-1xLAG-3 bispecific antibody, in patients (pts) with advanced solid tumors
    Day, D.
    Ganju, V.
    Chung, K.
    Si, L.
    Mao, L.
    Aghmesheh, M.
    Hoyer, R.
    Brewin, K.
    Zeng, S.
    Lu, Q.
    Jiang, C.
    Ren, F.
    Wu, X.
    Guo, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S625 - S625
  • [23] A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors.
    Hellmann, Matthew David
    Shimizu, Toshio
    Doi, Toshihiko
    Hodi, F. Stephen
    Rottey, Sylvie
    Aftimos, Philippe Georges
    Liu, Zhuqing Tina
    de Mendizabal, Nieves Velez
    Szpurka, Anna M.
    Piao, Yongzhe
    Vangerow, Burkhard
    Gandhi, Leena
    Leow, Ching Ching
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] MEDI5752, a novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors: First-in-human study
    Tran, Ben
    Voskoboynik, Mark
    Kim, Sang-We
    Lemech, Charlotte
    Carcereny, Enric
    Rha, Sun Young
    Ahn, Myung-Ju
    Felip, Enriqueta
    Lee, Ki H.
    Alvarez, Eduardo C.
    Yang, James Chih-Hsin
    Ascierto, Paolo A.
    Pulla, Mariano P.
    Freeman, Dan
    Song, Xuyang
    Gainer, Shelby D.
    Mitchell, Patrick
    Achour, Ikbel
    Subramaniam, Deepa S.
    Im, Seock-Ah
    CANCER RESEARCH, 2022, 82 (12)
  • [25] Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
    Hellmann, Matthew D.
    Bivi, Nicoletta
    Calderon, Boris
    Shimizu, Toshio
    Delafontaine, Brant
    Liu, Zhuqing Tina
    Szpurka, Anna M.
    Copeland, Victoria
    Hodi, F. Stephen
    Rottey, Sylvie
    Aftimos, Philippe
    Piao, Yongzhe
    Gandhi, Leena
    Galvao, Violeta Regnier
    Leow, Ching Ching
    Doi, Toshihiko
    CLINICAL CANCER RESEARCH, 2021, 27 (10) : 2773 - 2781
  • [26] A FIRST-IN-HUMAN TRIAL OF HSTC810 (ANTI-BTN1A1 AB), A NOVEL IMMUNE CHECKPOINT WITH A MUTUALLY EXCLUSIVE EXPRESSION WITH PD-1/PD-L1, IN PATIENTS WITH RELAPSED/REFRACTORY SOLID TUMORS
    Lee, Soohyeon
    Shin, Sangjoon
    Howie, Lynn
    Jung, Hyunjin
    Yoo, Steven
    Hong, David
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A773 - A773
  • [27] First-in-human dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/ refractory advanced solid tumors: Interim data
    Ahn, Eugene R.
    Duvivier, Herbert Leon
    Rasco, Drew W.
    Rethy, Agnes
    Moore, Chris
    Yuet, Amy
    Hankins, Sandra R.
    Orlandella, Rachael
    Khanna, Swati
    Dekker, Joseph
    Georgy, Angela
    Spigel, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] First-in-human, dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim data
    Van Tine, Brian A.
    Ahn, Eugene
    Redman, Rebecca A.
    Barve, Minal A.
    Edenfield, William J.
    Peguero, Julio
    Villaflor, Victoria M.
    Rasco, Drew W.
    Powell, Steven F.
    Mamuye, Admasu T.
    Moore, Chris B.
    Pelham, Joshua M.
    Charoenthongtrakul, Soratree
    Spigel, David R.
    CANCER RESEARCH, 2024, 84 (07)
  • [29] A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors
    Naing, Aung
    Gelderblom, Hans
    Gainor, Justin F.
    Forde, Patrick M.
    Butler, Marcus
    Lin, Chia-Chi
    Sharma, Sunil
    de Olza, Maria Ochoa
    Schellens, Jan H. M.
    Soria, Jean-Charles
    Taylor, Matthew H.
    Silva, Antonio P.
    Li, Zhonggai
    Bilic, Sanela
    Cameron, Scott
    Infante, Jeffrey R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] A phase I/IIa first-in-human study of PM1003 (anti-PD-L1 x 4-1BB bispecific antibody) in patients with advanced solid tumors
    Xue, J.
    Sun, Y.
    Li, D.
    Guo, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S629 - S629
12345